mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.
CAT No: R1901
CAS No: 1491152-26-1
Synonyms/Alias: mDPR-Val-Cit-PAB-MMAE;1491152-26-1;SCHEMBL17254422;CS-5430;DA-65306;HY-19813;G70025;
Chemical Name: N-[(2S)-3-Amino-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl]-L-valyl-N-{4-[(5S,8S,11S,12R)-11-[(2S)-2-butanyl]-12-(2-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenyl-2-propanyl]amino}-1-methoxy-2 ;-methyl-3-oxopropyl]-1-pyrrolidinyl}-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradec-1-yl]phenyl}-N5-carbamoyl-L-ornithinamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C65H100N12O15 |
M.W/Mr. | 1289.6 |
Application | Antibody-drug Conjugate |
InChI | InChI=1S/C65H100N12O15/c1-15-39(8)55(48(90-13)33-51(80)76-32-20-24-46(76)57(91-14)40(9)58(82)69-41(10)56(81)43-21-17-16-18-22-43)74(11)63(87)53(37(4)5)73-62(86)54(38(6)7)75(12)65(89)92-35-42-25-27-44(28-26-42)70-59(83)45(23-19-31-68-64(67)88)71-61(85)52(36(2)3)72-60(84)47(34-66)77-49(78)29-30-50(77)79/h16-18,21-22,25-30,36-41,45-48,52-57,81H,15,19-20,23-24,31-35,66H2,1-14H3,(H,69,82)(H,70,83)(H,71,85)(H,72,84)(H,73,86)(H3,67,68,88)/t39-,40+,41+,45-,46-,47-,48+,52-,53-,54-,55-,56+,57+/m0/s1 |
InChI Key | QJDGTZXZKQAVTL-IIMIZLLVSA-N |
Canonical SMILES | O=C([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC([C@@H](N1C(C=CC1=O)=O)CN)=O)=O)NC2=CC=C(COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N([C@H]([C@@H](CC(N3[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@@H](O)C4=CC=CC=C4)C)=O)C)CCC3)=O)OC)[C@@H](C)CC)C)=O)=O)=O)C=C2 |
1. High fat diet and GLP-1 drugs induce pancreatic injury in mice
4. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.